{
  "abstract": "Immunotherapy has revolutionized the treatment of multiple myeloma (MM), but durable immune control remains limited, increasing interest in how the bone marrow (BM) microenvironment influences antitumor immunity. BM adipocytes (BMAds) are increasingly recognized as metabolically active components of the BM. This review summarizes the current evidence linking BMAds to myeloma cell survival and immune cell function, particularly T cell activity. It also discusses their potential relevance to monoclonal antibodies, bispecific antibodies, and chimeric antigen receptor (CAR) T-cell therapy. Preclinical studies have shown that myeloma-associated BMAds undergo lipid depletion and acquire inflammatory and senescence-associated secretory features. BM lipid exposure is associated with impaired CD8+ T-cell metabolic fitness, whereas leptin receptor activation suppresses invariant natural killer T-cell anti-myeloma activity. Evidence concerning conventional natural killer cells and other immune compartments remains limited. Available clinical evidence is predominantly cross-sectional and therefore does not establish a direct role for BMAds in resistance to current immunotherapies or clarify whether they influence therapeutic target availability or function as clinically relevant bystander targets. Patient- and treatment-related factors, including aging and obesity, may further reshape the adipocytic-stromal and immune landscape of the marrow, potentially modifying local responses to immunotherapy. Future studies combining patient-derived multicellular models with spatial and longitudinal approaches should determine how BMAd-associated metabolic, inflammatory, and adipokine signaling affect immune control and treatment outcomes in MM and whether these processes can be therapeutically modulated.",
  "abstract_shown": true,
  "affiliations": [
    "Clinical Hematology Unit, Unidade Local de Saúde de Coimbra (ULS Coimbra), 3004-561 Coimbra, Portugal",
    "Institute of Physiology, Faculty of Medicine, University of Coimbra (FMUC), 3000-548 Coimbra, Portugal",
    "University Clinics of Hematology and Oncology and Laboratory of Oncobiology and Hematology, Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal",
    "Unidade Funcional de Citometria de Fluxo, ULS Coimbra, 3004-561 Coimbra, Portugal",
    "Faculty of Medicine, Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, 3000-548 Coimbra, Portugal",
    "Ciências Biomédicas Laboratoriais, ESTESC-Coimbra Health School, Instituto Politécnico de Coimbra, 3045-043 Coimbra, Portugal",
    "Group of Environmental Genetics of Oncobiology (CIMAGO), Faculty of Medicine, University of Coimbra (FMUC), 3004-504 Coimbra, Portugal",
    "Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, 3004-504 Coimbra, Portugal",
    "Clinical Academic Center of Coimbra (CACC), 3000-076 Coimbra, Portugal"
  ],
  "article_type": "review article",
  "arxiv": null,
  "author_total": 4,
  "authors": [
    {
      "affs": [
        0,
        1,
        2
      ],
      "name": "Adriana Roque",
      "orcid": "0000-0003-4194-9119"
    },
    {
      "affs": [
        3,
        4,
        5
      ],
      "name": "Artur Paiva"
    },
    {
      "affs": [
        1
      ],
      "name": "Raquel Seiça",
      "orcid": "0000-0002-8378-0895"
    },
    {
      "affs": [
        0,
        2,
        4,
        6,
        7,
        8
      ],
      "name": "Catarina Geraldes"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/b9hnvxn1bptgj.bib",
  "cited_by": 0,
  "doi": "10.3390/cancers18193213",
  "fulltext_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13663922/?tool=EBI",
  "id": "b9hnvxn1bptgj",
  "issns": [
    "2072-6694"
  ],
  "landing_url": "https://europepmc.org/article/PMC/PMC13663922",
  "language": "eng",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2720|Multiple Myeloma Research and Treatments"
    ]
  ],
  "openalex": "W7220438244",
  "pdf_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13663922/pdf/?tool=EBI",
  "pmcid": "PMC13663922",
  "pmid": null,
  "published": "2026-10-01",
  "publisher": "MDPI AG",
  "ris": "https://research.draconitic.com/paper/b9hnvxn1bptgj.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:35Z",
      "native_id": "PMC:PMC13663922",
      "source": "europepmc",
      "url": "https://europepmc.org/article/PMC/PMC13663922"
    },
    {
      "first_seen": "2026-10-30T12:19:58Z",
      "native_id": "10.3390/cancers18193213",
      "source": "crossref",
      "url": "https://www.mdpi.com/2072-6694/18/19/3213"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "issn:2072-6694",
      "subfield": "oncology"
    }
  ],
  "title": "Bone Marrow Adipocytes in Multiple Myeloma: Emerging Immunometabolic Interactions and Implications for Immunotherapy",
  "title_text": "Bone Marrow Adipocytes in Multiple Myeloma: Emerging Immunometabolic Interactions and Implications for Immunotherapy",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:19:58Z",
  "url": "https://research.draconitic.com/paper/b9hnvxn1bptgj",
  "venue": "Cancers",
  "versions": []
}